Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) reported new analyses from its HELIOS-B Phase 3 study showing that vutrisiran improved measures of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE